Sugi Predict

Sugi Predict / Compounds / SCHEMBL7032604

SCHEMBL7032604

SCHEMBL7032604

Nc1cc(Br)c2nc[nH]c2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.49
▸ ALDH1A1 P00352 3/20 0.49
▸ MEN1 O00255 3/20 0.49
▸ KMT2A Q03164 3/20 0.49
▸ PRNP P04156 1/20 0.49
▸ HPGD P15428 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ PNP P00491 1/20 0.46
▸ PRKCI P41743 1/20 0.46
▸ KDM4E B2RXH2 2/20 0.44
▸ RAD52 P43351 1/20 0.44
▸ APEX1 P27695 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ BLM P54132 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ MMP12 P39900 1/20 0.38
▸ C1S P09871 1/20 0.37
▸ CSNK2A2 P19784 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28871076 0.79 PNP (0.48) MAPTALDH1A1MEN1KMT2APRNP
SCHEMBL17698673 0.79 MEN1 (0.52) MAPTALDH1A1MEN1KMT2APRNP
SCHEMBL14916775 0.76 MEN1 (0.49) MAPTALDH1A1MEN1KMT2APRNP
SCHEMBL20385466 0.76 KMT2A (0.49) MAPTALDH1A1MEN1KMT2APRNP
SCHEMBL14723169 0.76 MEN1 (0.49) MAPTALDH1A1MEN1KMT2APRNP
SCHEMBL7028881 0.76 PNP (0.46) MAPTALDH1A1MEN1KMT2APRNP
SCHEMBL28370589 0.76 PNP (0.46) MAPTALDH1A1MEN1KMT2APRNP
SCHEMBL7035002 0.76 PNP (0.46) MAPTALDH1A1MEN1KMT2APRNP
SCHEMBL3071563 0.76 PNP (0.46) MAPTALDH1A1MEN1KMT2APRNP
SCHEMBL7090535 0.76 PNP (0.46) MAPTALDH1A1MEN1KMT2APRNP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200199247-A1 ANTIBODY CONJUGATES OF IMMUNE-MODULATORY COMPOUNDS AND USES THEREOF SILVERBACK THERAPEUTICS, INC. 2020-06-25 — — US disclosed
US-20200199247-A1 ANTIBODY CONJUGATES OF IMMUNE-MODULATORY COMPOUNDS AND USES THEREOF SILVERBACK THERAPEUTICS, INC. 2020-06-25 — — US disclosed
EP-3634401-A1 ANTIBODY CONSTRUCT CONJUGATES Silverback Therapeutics, Inc. (US) 2020-04-15 — — EP disclosed
EP-3634485-A1 ANTIBODY CONJUGATES OF IMMUNE-MODULATORY COMPOUNDS AND USES THEREOF Silverback Therapeutics, Inc. (US) 2020-04-15 — — EP disclosed
CN-110891605-A Antibody conjugates of immunomodulatory compounds and uses thereof 希沃尔拜克治疗公司 2020-03-17 — — CN disclosed
WO-2018227018-A1 ANTIBODY CONJUGATES OF IMMUNE-MODULATORY COMPOUNDS AND USES THEREOF SILVERBACK THERAPEUTICS, INC. (US) 2018-12-13 — — WO disclosed
WO-2018227023-A1 ANTIBODY CONSTRUCT CONJUGATES SILVERBACK THERAPEUTICS, INC. (US) 2018-12-13 — — WO disclosed
CN-103992310-B One group replaces benzo heterocyclic amine derivant and preparation method thereof and the related application as IMPDH inhibitor 中国医学科学院医药生物技术研究所 2016-07-06 — — CN disclosed
US-8778937-B2 Benzimidazole boronic acid derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2014-07-15 — — US disclosed
US-20130157977-A1 Benzimidazole Boronic Acid Derivatives As PI3 Kinase Inhibitors GLAXOSMITHKLINE LLC (US) 2013-06-20 — — US disclosed
US-20030022927-A1 Novel benzimidazole derivatives SYNAPTIC PHARMACEUTICAL CORPORATION 2003-01-30 — — US disclosed
US-6495583-B1 DRUG FOR TREATING AN ALPHA-2 ADRENERGIC RECEPTOR ASSOCIATED DISORDER, NASAL CONGENSTION AND ALLEVIATING PAIN SYNAPTIC PHARMACEUTICAL CORPORATION 2002-12-17 — — US disclosed
US-6436982-B1 USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS SYNAPTIC PHARMACEUTICAL CORPORATION 2002-08-20 — — US disclosed
US-20020072536-A1 Novel benzimidazole derivatives SYNAPTIC PHARMACEUTICAL CORPORATION 2002-06-13 — — US disclosed
US-6403626-B1 USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS SYNAPTIC PHARMACEUTICAL CORPORATION 2002-06-11 — — US disclosed
US-20020065307-A1 Novel benzimidazole derivatives SYNAPTIC PHARMACEUTICAL CORPORATION 2002-05-30 — — US disclosed
US-6316637-B1 SELECTIVE FOR CLONED HUMAN ALPHA 2 RECEPTORS AND ARE USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS SYNAPTIC PHARMACEUTICAL CORPORATION 2001-11-13 — — US disclosed
EP-0775134-A4 NOVEL BENZIMIDAZOLE DERIVATIVES SYNAPTIC PHARMA CORP (US) 1997-08-13 — — EP disclosed
EP-0775134-A1 Imidazolin-2-ylaminobenzimidazole derivatives SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1997-05-28 — — EP disclosed
WO-1996004270-A1 NOVEL BENZIMIDAZOLE DERIVATIVES SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1996-02-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020065307-A1 Novel benzimidazole derivatives OPRD1, OPRL1, OPRM1 MAPT 4094/4885ALDH1A1 938/4885MEN1 4620/4885
US-20020072536-A1 Novel benzimidazole derivatives OPRD1, OPRL1, OPRM1 MAPT 4095/4885ALDH1A1 923/4885MEN1 4680/4885
US-20030022927-A1 Novel benzimidazole derivatives OPRL1, OPRD1, OPRM1 MAPT 4207/4885ALDH1A1 1022/4885MEN1 4634/4885
US-20200199247-A1 ANTIBODY CONJUGATES OF IMMUNE-MODULATORY COMPOUNDS AND USES THEREOF LTK, TGFBR2, TNIK MAPT 1754/4885ALDH1A1 4625/4885MEN1 3689/4885
US-20130157977-A1 Benzimidazole Boronic Acid Derivatives As PI3 Kinase Inhibitors PI4KB, PI4KA, PIK3CB MAPT 3226/4885ALDH1A1 1470/4885MEN1 1952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.